Wiki · Longeva

Tissue repairBMP-7 (OP-1): a TGF-β family growth factor and the endogenous brake on TGF-β1BMP-7, or OP-1, is a recombinant TGF-β family growth factor, not a short synthetic peptide. It is the only molecule in this group that reached the operating room: as OP-1 it held FDA authorisation under a humanitarian device exemption before leaving the US market in 2014. This monograph covers why BMP-7 is better described as a brake on TGF-β1 than a repair signal, what the kidney models showed, endogenous antagonists, the carrier problem, the negative THR-184 phase 2, and what to check in an analytical package. RUO.

Tissue repairBPC-157 + TB-500: Tissue-Repair Peptide BlendThe two most-studied tissue-repair peptides — the stable gastroprotective BPC-157 and an actin-binding fragment of thymosin β4 (TB-500) — in one vial. What each one is, which mechanisms the literature attributes to them, which models they were studied in, and — with an honest limits section — where the evidence ends.

Tissue repairBPC-157: a pentadecapeptide for tissue-repair researchBPC-157 (Body Protection Compound-157): chemistry, sequence, directions of preclinical research and its status as a research reagent. A Longeva reference monograph.

Tissue repairTB-500 (Thymosin β4): actin, tissue repair and research statusTB-500 is a synthetic thymosin β4 (Tβ4) peptide that sequesters G-actin. Mechanism, preclinical tissue-repair data and research-use-only (RUO) status.